Programme overview
Download programme pdf >>
Note: the organisation keeps the right to make changes to the programme at any time.
-
08:00
Investors forum part 1 - breakfast session -
The investors forum is an exciting opportunity for those companies looking for equity capital and/or partnerships with companies and institutes across the life sciences value chain, from biotech, med tech and pharma companies to financiers and universities. The forum offers excellent opportunities for presenting your company or university to all major Dutch life sciences investors and discuss your business strategy, technology direction and capital-raising plan.
-
08:45
Present your company, products, technology or service. Open from 08:45 till 19:30 hours.
-
09:30
-
Welcome by chair Eline Vrijland-van Beest
Eline is chairing the plenary programme of the conference and will guide us through the day.
-
by Pancras Hogendoorn, Dean, vice-chairman of the executive board at the Leiden University Medical Center (LUMC)
-
by Menzo Havenga, President & CEO Batavia Biosciences
There is a constant demand for more affordable vaccines for global health (polio, measles, rubella), as well as new vaccines to protect against emerging virus outbreaks, such as Ebola, Lassa, Marburg, and coronavirus. To keep up with such demand, breakthrough technologies and global collaborations are required that allow flexible, cost-effective and rapid vaccine development. In this presentation, promising novel technologies, flexible manufacturing solutions and views on collaborations within the industry will be presented. These innovations have demonstrated to substantially lower the cost of goods and increase speed of manufacturing. Such innovations are deemed critical to stay ahead of the game and keep millions of people from dying from vaccine preventable diseases.
-
Startup climate in the Netherlands
Hosted by Pivot Park
André van de Sande, advisor to the Pivot Park and partner of the Venture Challenge programme, will give a presentation about the startup climate in the Netherlands.
-
Hosted by Health~Holland, Dr. ir. C.G.P. (Chrétien) Herben, Manager Valorisation
-
-
10:45
Time for networking and to visit the exhibition.
-
11:15
-
Advanced cell and gene based therapeutics
Hosted by Progress-PME
Presentations by:
▪ Barbara Sanders, Head of Vector Development at uniQure
▪ Marc Kamp, Senior Director QA CAR T Product Distribution, Supplier Quality & Regional GxP Compliance at Kite Pharma -
Human Microbiome: novel therapeutic strategies and market developments
Hosted by V.O. Patents & Trademarks
Presentations by:
▪ Dries Budding, CEO inBiome
▪ To be announced
-
-
12:45
Time for networking and to visit the exhibition.
-
14:00
-
Prevention of the onset of disorders by lifestyle changes - Why Small Changes Matter
Hosted by PwC
Presentations by:
▪ Karin Verzijden, Attorney at law at Axon Lawyers
▪ Hanno Pijl, Professor Diabetology at LUMC and Lifestyle4Health
▪ Jan Dekker, Managing Director FoodFirst Network -
Medical devices to respond to urgent needs
Hosted by QbD
Presentations by
▪ Steven Vinkx, QA & Regulatory Project Engineer at Quality by Design
▪ Koen Beyers, Founder & Board Member at Voxdale -
Action programme “New Opportunities for Top Sector Life Sciences & Health”
Presentation by
▪ Clémence Ross-van Dorp, Ministerie van Economische Zaken en Klimaat
-
-
16:00
Time for networking and to visit the exhibition.
-
16:30
-
Announcement winner Investors Forum
The winner of the Investors Forum will be awarded a partnering ticket, national or international with a total value of EUR 2,500 and will present their pitch.
-
Covid-19: developments in diagnostic tests, therapies and vaccines
Hosted by Axon Lawyers
Presentation by
▪ Anja Garritsen, CEO Innatoss Laboraties -
Hanneke Schuitemaker, Professor in Virology and VP Viral Vaccine Discovery & Translational Medicine at Janssen Vaccines & Prevention will give insights in the development of the Covid-19 vaccine at Janssen Vaccines in Leiden.
What happened from the moment the genetic sequence of SARS-CoV-2, was published and triggered an intense global R&D activity to develop a vaccine against the disease? The scale of the humanitarian and economic impact of the COVID-19 pandemic is driving evaluation of next-generation vaccine technology platforms through novel paradigms to accelerate development, market approval and manufacturing . Which strategy is applied by Janssen Vaccines?
-
-
17:45
Drinks, bites, visit exhibition and networking